TY - JOUR
T1 - Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21
AU - Owen, Bryn M.
AU - Mangelsdorf, David J.
AU - Kliewer, Steven A.
N1 - Funding Information:
This work was supported by National Institutes of Health (grant R01DK067158 to S.A.K. and D.J.M.), the Robert A. Welch Foundation (grants I-1558 to S.A.K. and I-1275 to D.J.M.), and the Howard Hughes Medical Institute (D.J.M.).
Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Fibroblast growth factors (FGFs) 15/19 and 21 belong to a subfamily of FGFs that function as hormones. Produced in response to specific nutritional cues, they act on overlapping sets of cell surface receptors composed of classic FGF receptors in complex with βKlotho, and regulate metabolism and related processes during periods of fluctuating energy availability. Pharmacologically, both FGF15/19 and FGF21 cause weight loss and improve both insulin-sensitivity and lipid parameters in rodent and primate models of metabolic disease. Recently, FGF21 was shown to have similar effects in obese patients with type 2 diabetes. We discuss here emerging concepts in FGF15/19 and FGF21 tissue-specific actions and critically assess their putative role as candidate targets for treating metabolic disease.
AB - Fibroblast growth factors (FGFs) 15/19 and 21 belong to a subfamily of FGFs that function as hormones. Produced in response to specific nutritional cues, they act on overlapping sets of cell surface receptors composed of classic FGF receptors in complex with βKlotho, and regulate metabolism and related processes during periods of fluctuating energy availability. Pharmacologically, both FGF15/19 and FGF21 cause weight loss and improve both insulin-sensitivity and lipid parameters in rodent and primate models of metabolic disease. Recently, FGF21 was shown to have similar effects in obese patients with type 2 diabetes. We discuss here emerging concepts in FGF15/19 and FGF21 tissue-specific actions and critically assess their putative role as candidate targets for treating metabolic disease.
KW - Arginine vasopressin
KW - Brown adipose tissue
KW - Corticotropin-releasing factor
KW - Hypothalamus
KW - Sympathetic nervous system
KW - βKlotho
UR - http://www.scopus.com/inward/record.url?scp=84920483737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920483737&partnerID=8YFLogxK
U2 - 10.1016/j.tem.2014.10.002
DO - 10.1016/j.tem.2014.10.002
M3 - Review article
C2 - 25476453
AN - SCOPUS:84920483737
SN - 1043-2760
VL - 26
SP - 22
EP - 29
JO - Trends in Endocrinology and Metabolism
JF - Trends in Endocrinology and Metabolism
IS - 1
ER -